Management of Past EBV Infection with Ongoing Viral Shedding

Interpretation of Laboratory Results

A serologic profile with VCA IgM <36 (negative) rules out acute primary infection, while VCA IgG 151 U/ml (positive) confirms past EBV exposure, and EBNA IgG <18 (negative) suggests either recent past infection or atypical serologic response, according to the Clinical Infectious Diseases guidelines 3
The combination of positive VCA IgG with negative EBNA IgG typically indicates infection within the past 3-6 months, though EBNA may remain negative in some individuals indefinitely, as stated by the Clinical Infectious Diseases guidelines 3

Antiviral medications, such as acyclovir, valacyclovir, and ganciclovir, are completely ineffective against latent EBV and are not recommended for past EBV infections or asymptomatic viral shedding, as recommended by the Praxis Medical Insights guidelines 1, 2

A throat PCR level of 600 copies/ml is considered low and has no clinical significance in the absence of symptoms, according to the Haematologica guidelines 4
Monitoring is not routinely recommended for immunocompetent individuals with past EBV infection, as stated by the Praxis Medical Insights guidelines 2

Active management should only be pursued if the patient develops persistent symptoms, including fever, significant lymphadenopathy, or hepatosplenomegaly, which would raise concern for chronic active EBV (CAEBV), as recommended by the Praxis Medical Insights guidelines 1
Immunocompromised individuals, such as transplant recipients or those with HIV, require regular EBV DNA-emia monitoring in blood and potential preemptive rituximab therapy for significant viremia, according to the Haematologica guidelines 4, 5, 2
EBV-associated lymphoproliferative disease requires rituximab 375 mg/m² weekly for 1-4 doses as first-line therapy, as recommended by the Haematologica guidelines 4, 5

Antivirals should not be prescribed based solely on positive throat PCR or serologic evidence of past infection, as this is ineffective and not evidence-based, according to the Praxis Medical Insights guidelines 1, 2
Asymptomatic viral shedding should not be confused with active disease, and throat shedding can occur even in the complete absence of circulating B cells, as stated by the Haematologica guidelines 4
EBV DNA levels should not be monitored serially in immunocompetent patients, as this leads to unnecessary interventions without clinical benefit, as recommended by the Praxis Medical Insights guidelines 2
Throat PCR should not be used for clinical decision-making, and blood EBV DNA quantification is the appropriate test if monitoring is needed in high-risk populations, according to the Haematologica and Clinical Infectious Diseases guidelines 4, 3